|
New class of drugs can reverse fibrosis in injured and diabetes-afflicted kidneys. |
 |
 |
|
EurekAlert: Soon after the BIDMC team identified the key receptor Alk3 in the lab, they collaborated with a Canadian biotechnology company, Thrasos Therapeutics, interested in developing targeted therapies for the prevention and treatment of severe organ failure, especially kidney disease. Based on the details about the molecular interaction between the BMP protein and the ALK receptor, company scientists developed a class of small functional peptides, including THR-123, which then underwent further testing.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
